The FDA approved the first generic version of Xofluza (baloxavir marboxil) on June 17, clearing Norwich Pharmaceuticals’ single-dose influenza tablet ahead of the 2026–27 flu season.
Generic baloxavir marboxil is approved to treat acute uncomplicated influenza in patients 5 and older who have been symptomatic for no more than 48 hours. It’s also approved for post-exposure prophylaxis for the same age group.
The drug works by inhibiting a viral enzyme called cap-dependent endonuclease, a mechanism distinct from older antivirals such as Tamiflu.
The new medication will offer patients a lower-cost version of the branded Xofluza, a registered trademark of Genentech.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.